Akeso's First Bispecific ADC (Trop2/Nectin4 ADC) Enters Clinical Trials, Strengthening Leadership in 'IO+ADC' 2.0 Strategy ...Middle East

HONG KONG, July 3, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") has announced the successful enrollment of the first patient in its Phase Ia clinical trial for AK146D1, a bispecific Antibody-Drug Conjugate (ADC) targeting Trop2 and Nectin4. AK146D1 is Akeso's...

Hence then, the article about akeso s first bispecific adc trop2 nectin4 adc enters clinical trials strengthening leadership in io adc 2 0 strategy was published today ( Thursday 03/07/2025 - 09:49 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso's First Bispecific ADC (Trop2/Nectin4 ADC) Enters Clinical Trials, Strengthening Leadership in 'IO+ADC' 2.0 Strategy )

Also on site :

• Hollywood mourns loss of beloved makeup artist Jasen Kaplan
• Suspected mountain lion attack in Colorado mountains under investigation
• Person falls to death on Boylston Street on New Year’s Eve